Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

ADVANCED SOLID TUMORS

Interventions

DRUG

PM01183

Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion

Trial Locations (2)

Cancer Research Center. University of Chicago Hospitals., Chicago

Vall d'Hebron University Hospital., Barcelona